Iovance Biotherapeutics (IOVA) Projected to Post Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.1335) per share and revenue of $87.6740 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Iovance Biotherapeutics (NASDAQ:IOVA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The firm had revenue of $71.43 million for the quarter, compared to the consensus estimate of $77.84 million. Iovance Biotherapeutics had a negative net margin of 123.92% and a negative return on equity of 50.17%. The business’s quarterly revenue was up 44.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) EPS. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $4.36 on Wednesday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -4.59 and a beta of 0.71. The firm has a fifty day moving average price of $4.32 and a two-hundred day moving average price of $3.74. Iovance Biotherapeutics has a fifty-two week low of $1.76 and a fifty-two week high of $5.64.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Chardan Capital lowered their target price on Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Iovance Biotherapeutics has an average rating of “Hold” and a consensus price target of $8.43.

Institutional Investors Weigh In On Iovance Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. bought a new position in shares of Iovance Biotherapeutics during the 3rd quarter worth approximately $84,000. Envestnet Asset Management Inc. boosted its stake in Iovance Biotherapeutics by 112.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 47,466 shares of the biotechnology company’s stock valued at $82,000 after buying an additional 25,083 shares in the last quarter. Russell Investments Group Ltd. grew its position in Iovance Biotherapeutics by 372.4% in the second quarter. Russell Investments Group Ltd. now owns 40,347 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 31,807 shares during the period. Xponance LLC grew its position in Iovance Biotherapeutics by 19.4% in the fourth quarter. Xponance LLC now owns 24,288 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 3,950 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new position in Iovance Biotherapeutics during the third quarter worth $60,000. 77.03% of the stock is owned by institutional investors and hedge funds.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.